Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-09

Clinical Trial Update: A Study of Guselkumab in Participants With Systemic Sclerosis [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluating guselkumab in systemic sclerosis has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Scleroderma, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2024-10-09